
VahatiCor Launches U.S. Clinical Trials for CMD Heart Implant
At Yale-New Haven Hospital, clinicians have enrolled the first American patient in the SERRA-I study, marking the entry of VahatiCor’s A-FLUX Reducer System into the U.S. market for investigation. The trial targets coronary microvascular dysfunction, a condition causing persistent chest pain that remains largely unaddressed by current cardiac therapies.

























